MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Ofatumumab (Kesimpta®, Arzerra®)

Selected References:

  • Dobson R, et al. 2023. Anti-CD20 therapies in pregnancy and breast feeding: A review and ABN guidelines. Pract Neurol; 23(1):6-14.
  • Hauser SL, et al. 2022. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5?years. Mult Scler. 2022 Sep;28(10):1576-1590.
  • Hellwig K, et al. 2022. Pregnancy outcomes in patients with multiple sclerosis following exposure to ofatumumab (P4-4.007). Neurology. Neurology, 98 (18 Supplement)
  • Novartis Pharmaceuticals Corporation. 2022. Kesimpta® (ofatumumab) Prescribing Information. Available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a8a3f53-2062-48ff-9dbe-b939df133ca3&audience=consumer
  • Novartis Pharmaceuticals Corporation. 2022. Arzerra® (ofatumumab) Prescribing Information. Available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77785ce3-e8df-4ca1-8f8e-6c418c6a17de&audience=consumer
  • Quattrocchi E, Ostergaard M, Taylor PC, van Vollenhoven RF, Chu M, Mallett S, Perry H, Kurrasch R. 2016. Safety of repeated open-label treatment courses of intravenous ofatumumab, a human anti-cd20 monoclonal antibody, in rheumatoid arthritis: Results from three clinical trials. PLoS One. Jun 23;11(6): e0157961.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.